Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Stock Price Dropped 8.8% Last Week; Individual Investors Would Not Be Happy
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) Stock Price Dropped 8.8% Last Week; Individual Investors Would Not Be Happy
Key Insights
关键见解
- Significant control over Luoxin Pharmaceuticals Group Stock by individual investors implies that the general public has more power to influence management and governance-related decisions
- The top 9 shareholders own 51% of the company
- 12% of Luoxin Pharmaceuticals Group Stock is held by insiders
- 个人投资者对罗欣制药集团股票的严格控制意味着公众拥有更大的影响管理和治理相关决策的权力
- 前9名股东拥有公司51%的股份
- 罗欣制药集团12%的股票由内部人士持有
A look at the shareholders of Luoxin Pharmaceuticals Group Stock Co., Ltd. (SZSE:002793) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 44% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
看看罗欣药业集团股票有限公司(深圳证券交易所:002793)的股东可以告诉我们哪个集团最强大。我们可以看到,个人投资者拥有公司的大部分股份,所有权为44%。换句话说,该集团面临最大的上行潜力(或下行风险)。
And following last week's 8.8% decline in share price, individual investors suffered the most losses.
继上周股价下跌8.8%之后,个人投资者遭受的损失最大。
Let's take a closer look to see what the different types of shareholders can tell us about Luoxin Pharmaceuticals Group Stock.
让我们仔细看看不同类型的股东能告诉我们有关罗欣制药集团股票的哪些信息。
![1724457830160](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240824/42821417-0-39045fb0f883683b7a7dabca8bdbb109.webp/bigjpg)
What Does The Institutional Ownership Tell Us About Luoxin Pharmaceuticals Group Stock?
关于罗欣制药集团的股票,机构所有权告诉我们什么?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。
We can see that Luoxin Pharmaceuticals Group Stock does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Luoxin Pharmaceuticals Group Stock's earnings history below. Of course, the future is what really matters.
我们可以看到,罗欣制药集团的股票确实有机构投资者;他们持有该公司很大一部分股票。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时会像所有人一样进行不良投资。如果多家机构同时改变对股票的看法,你可能会看到股价快速下跌。因此,值得在下面查看罗欣制药集团股票的收益记录。当然,未来才是真正重要的。
![1724457831020](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240824/42821417-1-3beba7cf56bd396d0ddfa3eae02da8be.webp/bigjpg)
Luoxin Pharmaceuticals Group Stock is not owned by hedge funds. Shandong Luoxin Holdings Co., Ltd is currently the largest shareholder, with 22% of shares outstanding. Xiubao Fang is the second largest shareholder owning 9.2% of common stock, and Ally Bridge Group holds about 4.3% of the company stock.
罗欣制药集团的股票不归对冲基金所有。山东罗欣控股有限公司目前是最大股东,已发行股份的22%。方秀宝是第二大股东,拥有9.2%的普通股,盟桥集团持有公司约4.3%的股份。
We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
我们进一步挖掘发现,9名大股东约占登记册的51%,这意味着除了较大的股东外,还有一些较小的股东,从而在一定程度上平衡了彼此的利益。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
虽然研究公司的机构所有权可以为您的研究增加价值,但研究分析师的建议以更深入地了解股票的预期表现也是一种好做法。据我们所知,没有分析师对该公司进行报道,因此它可能处于雷达之下。
Insider Ownership Of Luoxin Pharmaceuticals Group Stock
罗欣制药集团股票的内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
不同国家对内部人员的定义可能略有不同,但董事会成员总是计算在内。公司管理层经营业务,但首席执行官将向董事会负责,即使他或她是董事会成员。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。
It seems insiders own a significant proportion of Luoxin Pharmaceuticals Group Stock Co., Ltd.. Insiders have a CN¥467m stake in this CN¥4.0b business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
内部人士似乎拥有罗欣制药集团股份有限公司的很大一部分股份。内部人士在这项40元人民币的业务中持有46700万元人民币的股份。这可能表明创始人仍然拥有大量股份。你可以点击这里查看他们是否在买入或卖出。
General Public Ownership
一般公有制
The general public-- including retail investors -- own 44% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
包括散户投资者在内的公众拥有该公司44%的股份,因此不容忽视。虽然这个团体不一定能做主,但它肯定会对公司的运营方式产生真正的影响。
Private Company Ownership
私人公司所有权
We can see that Private Companies own 28%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我们可以看到,私人公司拥有28%的已发行股份。私营公司可能是关联方。有时,内部人士通过控股私营公司而对上市公司拥有权益,而不是以个人身份拥有权益。尽管很难得出任何宽泛的结论,但值得注意的是,这是一个需要进一步研究的领域。
Next Steps:
后续步骤:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for Luoxin Pharmaceuticals Group Stock (of which 1 can't be ignored!) you should know about.
我觉得看看究竟谁拥有一家公司非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。比如风险。每家公司都有它们,我们已经发现了罗欣制药集团股票的3个警告信号(其中1个不容忽视!)你应该知道。
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
如果你更愿意去另一家公司看看,一家财务状况可能更好,那么千万不要错过这份由强劲财务数据支持的有趣公司的免费名单。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。